Announcements - OBI Pharma 台灣浩鼎

2021.Oct.27

OBI-866 ”Immunogenic/Therapeutic Glycan Compositions And Uses Thereof“ Was Granted By Taiwan Intellectual Property Office

2021.Oct.25

Application of Investigational Device Exemption for Immunohistochemistry applied to Phase II Clinical Trial of OBI-999, has been granted by FDA

2021.Oct.21

The Globo H Antibody Drug Conjugate, OBI-999, has been granted by TFDA to proceed to Phase II Human Clinical Study

2021.Oct.13

OBI filed an Application of Phase II human clinical trial for Globo-H Antibody Drug Conjugate, OBI-999, to TFDA

2021.Sep.29

OBI Filed an Application of Investigational Device Exemption (IDE) for Phase II Cohort Expansion Human Clinical Trial for Globo H Antibody Drug Conjugate, OBI-999, to FDA

2021.Sep.09

Announcement on behalf of Amaran Biotechnology, Inc., a major subsidiary, that the Company’s Board of Directors resolved to revise the Regulations for Issuance and Subscription of 2020 Employee Stock Options

2021.Sep.09

Announcement on behalf of Amaran Biotechnology, Inc., a major subsidiary, that the company’s Board of Directors resolved to change the date for 2021 annual shareholders’ meeting

2021.Sep.07

Supplementary announcement of electronic voting shareholders’ complimentary gift for 2021 annual shareholders’ meeting

2021.Aug.06

The Company’s Board of Directors resolved to issue employee stock options and the subscription rules

2021.Aug.06

New appointment of Audit Committee member

News

Latest News

Events

Latest events